Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.54 |
| ▸ | ITGAV | P06756 | 13/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.48 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13355502 | 0.88 | CXCR4 (0.68) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355316 | 0.84 | CXCR4 (0.76) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355198 | 0.83 | CXCR4 (0.62) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL12705294 | 0.82 | APP (0.60) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355372 | 0.81 | CXCR4 (0.74) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355324 | 0.81 | CXCR4 (0.77) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355328 | 0.81 | CXCR4 (0.77) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355414 | 0.80 | CXCR4 (0.76) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355454 | 0.80 | CXCR4 (1.00) | CXCR4ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL13355391 | 0.80 | ITGB3 (0.65) | CXCR4ITGB3ITGAVITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010057101-A2 | COMPOUNDS USEFUL AS HIV BLOCKERS | SCHERING CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |